Xlife Sciences AG Reports Success in Liver Diagnostics – x-nuclear diagnostics GmbH Achieves Market Readiness

Xlife Sciences AG

/ Key word(s): Market launch/Product Launch

Xlife Sciences AG Reports Success in Liver Diagnostics – x-nuclear diagnostics GmbH Achieves Market Readiness

26.06.2024 / 07:00 CET/CEST

Zurich, 26th of June 2024: Xlife Sciences AG announces significant progress in the development and application of innovative diagnostic solutions. The project company x-nuclear diagnostics GmbH, a 100% subsidiary of Xlife Sciences AG, has achieved remarkable success in the research and application of the new PET tracer DAZAmed.

A PET tracer is a special substance used in positron emission tomography (PET) to visualize organ functions in the body. These tracers are radioactive molecules that bind to specific structures in the body and emit radiation, allowing detailed images of organs and their functions to be created.

The PET tracer DAZAmed is the first of its kind developed specifically for visualizing liver function. Initial applications have already successfully diagnosed patients, underscoring the efficacy and reliability of this innovative diagnostic tool. Additionally, a successful toxicity study in animals and trials in patients have confirmed the safety, tolerability, and efficacy of the tracer.

Another significant advancement is the GMP-compliant production of the precursors of DAZAmed (excluding the radioactive ligand) by inflamed pharma GmbH, a 70% subsidiary of Xlife Sciences AG, which meets production standards and quality requirements, thus paving the way for clinical commercialization. This further highlights the enormous synergy potential of Xlife Sciences AG’s highly diversified project portfolio.

The rollout of the DAZAmed PET tracer is planned for the third quarter of 2024, with initial revenues expected in Germany. The DAZAmed PET tracer will be used in liver diagnostics for patients, representing an important milestone in medical imaging and diagnostics.

Oliver R. Baumann, CEO of Xlife Sciences AG, comments on this progress: «We at Xlife Sciences AG are proud to have reached another significant milestone in medical diagnostics. The development and successful application of the liver-specific PET tracer DAZAmed by our subsidiary x-nuclear diagnostics GmbH is further proof of the innovative strength and commitment of our team.»

With these developments, Xlife Sciences AG continues its mission to advance innovative and future-oriented technologies in healthcare and improve access to advanced diagnostic solutions.

 

Financial calendar

Annual Shareholders Meeting 2024 28 June 2024
Half-Year Report 2024 19 September 2024

Xlife Sciences AG, 
Talacker 35, 
8001 Zurich, 
Switzerland,
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch
Commercial Register Zurich CHE-330.279.788 
Stock Exchange: SIX Swiss Exchange

Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, dennis.fink@xlifesciences.ch

About Xlife Sciences AG (SIX: XLS) 

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch 

Disclaimer 

Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements. 


End of Media Release


show this